accret multipl level
one best-receiv deal health care year isnt hot
biotechnolog compani drug giant megamerg take-over
busi sell product keep medic research pipelin hum
februari ge announc agreement wherebi
acquir busi ge biopharma
cash buy pharmaceut diagnost
busi busi consist mostli slower-grow lower-margin
product group like contrast media molecular imag consum
net tax benefit pay
use combin cash hand debt cash rais two equiti
offer common offer prefer offer
fund deal pay expect ebitda around
forward revenu expect per share ep accret year
one per share accret year five
dhr acquisit busi good move
compani deal masterstrok ge allow ge pare
debt load ge deal bring badly-need cash help
shore busi ceo larri tri turn hamstrung behemoth
crown jewel acquisit put
forefront drug biotech sector hottest field fix seriou health
condit molecular level modifi cell dna grow new
protein suppli machin materi help compani
develop new therapi benefit industri growth
without take stock-kil risk drug trial fail
see meaning opportun har power
busi system provid custom end-to-
end bioprocess solut help enabl breakthrough develop
danah corpor announc februari enter
definit agreement compani acquir
biopharma busi cash purchas price
transact expect complet subject
customari condit includ receipt applic regulatori approv
busi establish stand-alon oper compani within
life scienc segment join compani pall beckman
phenomenex busi
expect financ all-cash transact proce
equiti offer may includ offer mandatori convert
prefer share remaind avail cash hand proce
issuanc debt and/or new credit facil new debt expect
issu blend interest rate
integr busi within danah busi system provid faster
innov well cost synergi time seen year three
onward term activ compani activ across globe
larg contribut major geograph region expect grow
per year
estim acquisit reduc dilut net ep
accret non-gaap adjust dilut net ep
first full year post acquisit
amort purchas account charg transact expens
attribut acquisit well stand-up cost relat carv
busi dilut impact anticip equiti financ
transact includ non- dilut ep figur
acquisit enhanc already-strong posit
attract grow market equip consum use
produc rang biolog pharmaceut product includ antibodi
vaccin gene therapi
ge biopharma lead provid instrument consum softwar
support research discoveri process develop manufactur
workflow biopharmaceut drug busi compris process
chromatographi hardwar consum cell cultur media single-us
technolog develop instrument consum servic
ge biopharma expect gener annual revenu
revenu consid recur given anticip tax
benefit transact structur net purchas price
repres multipl time expect ebitda
ge biopharma renown provid best-in-class bioprocess
technolog solut deal pivot mileston
demonstr ge execut strategi take thought
deliber action reduc leverag strengthen balanc sheet
share gain much biggest intra-day gain decad
share rose februari ge jump
ahead regular trade new york ge jump close
new york highest level sinc oct share advanc
year best perform standard poor sub-index industri
acquisit bring talent passion team well highli
innov industry-lead product suit life scienc portfolio
provid excel complement current biolog workflow solut
ge biopharma lead provid instrument consum
softwar support biolog product workflow research discoveri
process develop manufactur
ge biopharma well posit compel long-term growth driver
prolifer cell gene therapi
gener electr decid separ core part
busi concentr focu area aviat power renew
energi ge began readi paperwork ipo healthcar busi
complet spin-off decid sell busi rather initi
bio-pharma unit manufactur equip special resin help
pharmaceut compani discov mass produc biopharmaceut
like humira remicad rituxan design fight autoimmun
diseas rheumatoid arthriti psoriasi
also help vaccin develop research explor immunotherapi
emerg type treatment use virus tool reprogram
har bodi immun cell help immun system sniff kill
cancer diseas
ge said would retain second key part life scienc
busi pharmaceut diagnost unit develop contrast media use
radiologist unit global leader pharmaceut diagnost medic
imag use patient procedur year
ge healthcar global instal base imag mobil
diagnost monitor unit busi exclud bio-pharma
unit gener revenu busi leader imag
monitor diagnost also provid servic accessori educ
train consult
ge biopharma primarili compris bioprocess expect
gener annual revenu within bioprocess upstream
compris annual revenu organ growth
includ cell cultur media singl use technolog lab develop system
consum downstream organ growth includ
chromatographi consum softwar servic
revenu busi includ lab filtrat
genom consum low-mid singl digit growth revenu
revenu product line
strong revenu growth continu margin expans
maintain buy rate maintain tp
estim tp base forward price-to-earnings
multipl ep give
upsid potenti due declin
stock price last one-month also estim top
line revenu growth
estim base follow factor strong growth
revenu strong margin expans double-digit growth
ep newli launch product acquisit
danah deliv strong perform quarter
growth revenu strong oper margin double-digit
growth ep four five platform deliv mid-
total revenu increas
oper margin increas net earn
increas adjust ep
increas ep increas
geograph high growth market revenu double-
digit china india lead way develop
market mid-single-digit growth led momentum
north america western europ
life scienc report revenu increas
due high-singl digit core revenu growth
beckman life scienc due new product launch
sciex deliv high-single-digit core revenu growth due
growth north america china saw strength across
pharmaceut food test end market
region driven part demand sciex recent launch
compani name corporationtickerdhrstock ratingbuyunchangedindustri viewoverweightpositivepric oct week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth corporation| march
sinc acquisit pall alreadi achiev
annual cost save
target help increas gross margin close
bp oper margin bp
acquir ago busi
great start part deliv mid-teen revenu
growth quarter
diagnost segment deliv revenu growth
due growth immunoassay strength
autom recent launch hematolog product
cepheid deliv double-digit core revenu growth
continu innov leader quarter
expect adjust dilut ep guidanc
rang assum core revenu
growth adjust dilut ep expect
rang
current price-to-earnings multipl
averag price-to-earnings price-to-earnings fell
due fall stock price last one-month sinc
price-to-earnings went due
increas stock price strong perform
compani expect forward price-to-earnings multipl
recommend buy rate base
perform period stock gave
neg return quarter declin
month octob maintain tp give
upsid potenti despit strong growth
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date oct ex-dividend date sep last split factor new per last split date jul inform danah corporation| march
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg oper profit interest incom interest minor incom incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli corporation| march
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item danah corporation| march
oper cash flow continu oper increas period
due increas net earn continu oper
net cash use invest activ continu oper period
compar
financ activ continu oper provid cash period
compar cash use increas due higher net proce
commerci paper borrow compani issu commerci paper pay
portion acquisit price april
defer incom taxes- oper increas decreas increas decreas current assets- decreas increas decreas increas current decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu issuanc capit repurchas capit stock- payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end corporation| march
danah deliv strong result due strong growth revenu
strong oper margin expans double-digit growth adjust ep
compar
total revenu increas compar
revenu impact currenc translat led
declin revenu acquisit ad growth revenu
revenu four five platform deliv mid-single-
digit better core growth
gross profit increas
compar
decreas
compar
geograph high-growth develop market contribut core
sale growth revenu high-growth market increas
doubl digit rate compar due continu
strength china high-growth market repres
total sale revenu develop market increas mid-
singl digit rate due growth north america
cog increas compar
due impact higher y/i sale volum includ sale
recent acquir busi partli off-set increment y/i cost save
associ restructur continu product improv
action taken
gross profit increas compar
gross margin decreas compar
decreas gross margin quarter due
impact foreign currenc exchang rate quarter includ
declin gross margin partial off-set impact higher y/i
sale volum includ sale recent acquir busi increas
leverag certain manufactur cost increment y/i cost save
associ restructur activ continu product
improv action taken
increas
compar
gaap ep increas
compar
sg expens increas compar
sg declin compar
due benefit increas leverag dhr gener
administr cost base result higher sale volum partial
off-set continu invest sale market growth initi
 expens increas compar
 flat total revenu
oper profit increas compar
oper margin total revenu
compar total revenu
interest expens increas compar
increas due higher averag interest rate
outstand borrow compar averag interest
rate partial off-set lower averag outstand commerci
paper borrow compar
effect tax rate compar
effect tax rate includ net tax benefit relat
releas valuat allow associ certain foreign oper loss
excess tax benefit stock-bas compens aggreg
reduc report tax rate
net incom increas compar
ep increas
compar non-gaap ep increas
compar
period total revenu increas
compar cog increas
compar due impact higher y/i sale
volum includ sale recent acquir busi partli off-set
increment y/i cost save associ restructur continu
product improv action taken
period gross profit increas
compar gross margin period
compar increas due impact
higher y/i sale volum includ sale recent acquir busi
increas leverag certain manufactur cost increment y/i cost
save associ restructur activ continu product
improv action taken
period sg expens increas
compar sg declin compar
impact restructur impair
relat charg incur relat discontinu product line also
contribut y/i decreas sg expens sale
period
period expens increas
compar flat total revenu
period oper profit increas
compar oper margin
compar
period interest expens
compar impact foreign currenc exchang
rate also contribut higher interest expens
period effect tax rate compar
period net incom increas
compar ep increas
compar
gross profit increas
compar
increas
compar
danah report segment includ life scienc diagnost dental
total revenu life scienc segment increas
compar period total
revenu increas compar
price increas segment contribut sale growth y/i
basi three nine-month period
oper profit increas compar
oper margin increas
compar
sale busi broad rang mass spectromet grew y/i
basi period led strong sale
growth high-growth market particularli china rest asia
sale microscopi product grew three nine-month
period across major end-market due demand relat
releas new product
geograph demand microscopi product increas north america
high-growth market primarili china demand busi flow
cytometri particl count product line strong across major
geographi led north america china three nine-month
period western europ nine-month period
new product launch also contribut increas demand
sale filtrat separ purif technolog increas across
major geographi three nine month period
increas due continu growth biopharmaceut
microelectron fluid technolog asset protect end-market well
laboratori food beverag end-market period
total revenu life
scienc increas
compar
sale filtrat
separ
increas across
major geographi
three nine
month period
sale growth acquisit due acquisit april
provid addit sale earn growth opportun segment
expand segment product line divers includ new product
servic offer area genom consum potenti
futur acquisit complementari busi
total revenu diagnost segment increas
compar period total
revenu increas compar
price segment neg impact sale growth y/i
basi three nine-month period
oper profit decreas compar
oper margin increas
compar
period core sale grew molecular
diagnost busi driven strong growth develop high-growth
sale segment clinic lab busi increas y/i basi
three nine-month period due increas demand high-
growth market led china partial off-set develop market
period increas demand due
immunoassay autom product line sale acut care
diagnost busi increas y/i three nine-month period
due continu strong sale blood ga immunoassay product
line across major geographi particularli strong growth
sale acut
increas y/i
three nine-month
period due
continu strong sale
blood ga
line across major
geographi
growth high-
sale patholog diagnost busi grew y/i three
nine-month period led demand new product
advanc stain core histolog product line sale patholog
diagnost busi increas across major geographi led north
america western europ china three nine-month period
total revenu dental segment decreas
compar total revenu increas
compar price
segment neg impact sale growth y/i basi
three nine-month period
oper profit decreas compar
oper margin declin
compar
geograph y/i core revenu declin three nine-month
period driven growth high-growth market primarili china
russia off-set declin north america
lesser extent western europ japan
revenu growth specialti consum busi consist
implant system orthodont product led china north
america three nine-month period
sale dental equip tradit dental consum declin
three nine-month period due declin north
america three nine-month period lower core sale
dental equip tradit dental consum product line north
america off-set y/i growth specialti consum
categori primarili reflect impact inventori reduct sever
distribut partner well impact realign distributor
manufactur dental industri
total revenu
decreas
compar
sale dental
equip
consum declin
three nine-
month period
due declin north
juli announc intent spin-off dental busi
independ publicli trade compani dental separ
dental busi sale year-end decemb
transact expect tax-fre compani sharehold
target complet dental separ subject
satisfact certain condit includ obtain final approv
danah board director satisfactori complet financ receipt tax
opinion receipt favor rule ir receipt
total sale environment appli solut segment increas
compar
month period total revenu increas
compar price increas segment contribut
sale growth y/i basi three nine-month
period respect
oper profit increas compar
oper margin compar
sale segment water qualiti busi increas low doubl
digit rate three-month period high-singl digit
rate nine-month period y/i core sale analyt
instrument product line grew three nine-month period
driven higher demand across major geographi led china
north america western europ
revenu growth busi chemic treatment solut product line
three nine-month period driven higher demand
primari metal mine food beverag commerci institut
end-market partial off-set lower demand oil ga chemic
announc intent
spin-off dental
busi
trade compani
total sale
increas
compar
geograph y/i core revenu growth chemic treatment solut
due increas demand north america high-growth market
three nine-month period
sale busi ultraviolet water disinfect product line
increas three nine-month period due
continu strength municip end-market
geograph y/i demand ultraviolet water disinfect product
driven higher demand north america north america
high-growth market primarili china nine-month period partial off-set
softer demand western europ period china
sale segment product identif busi increas
mid-singl digit rate three nine-month period
major core revenu growth driven strong demand mark
code equip relat consum across major end-market
major geographi led western europ north america high-
demand packag color solut product servic decreas
slightli three nine-month period geograph y/i
core revenu growth packag color solut product servic
soften develop high-growth market
nine-month period weaker demand high-growth market slightli
off-set increas demand develop market
sale
three
nine-month period
due
continu strength
revenu growth
packag color
solut product
servic soften
develop high-
growth market
deliv
core growth
achiev
combin new
execut strateg
acquisit
increas exposur
attract end
guidanc conclus
expect ep rang non-gaap
adjust ep expect rang
expect adjust ep ep
rang
danah deliv strong result revenu growth
growth net earn adjust ep increas
period deliv core growth
achiev combin new product innov strong
commerci execut strateg acquisit increas
exposur attract end market
geograph high growth market revenu double-digit china
india lead way develop market mid-single-digit growth
led momentum north america western europ gener
free cash flow ytd result free cash flow-to-net incom
convers ratio
beckman life scienc deliv high-single-digit core revenu growth
posit result across major product line geographi
sinc acquisit pall achiev annual cost
save deliv double-digit growth revenu quarter
acquir ago busi great start part
deliv mid-teen revenu growth quarter
beckman coulter core revenu growth low-singl digit strength
china partial off-set soft develop market growth
diagnost platform due immunoassay strength autom
continu deliv strong top-lin result recent acquisit
invest innov db growth tool driven better
perform share gain across mani busi
non- reconcili
non- reconcili
non- reconcili
gross margin increas ttm basi compar due decreas cog
oper margin increas ttm basi compar
y/i revenu growth increas ttm basi compar
ep growth ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth corporation| march
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale danah corporation| march
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset danah corporation| march
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item danah corporation| march
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas investment- sale issuanc repurchas stock- net issuanc prefer stock- net issuanc net chang capit free corporation| march
current price-to-earnings multipl averag price-to-earnings price-to-earnings fell
due fall stock price last one-month sinc price-to-earnings went avg-
due increas stock price strong perform compani expect forward
price-to-earnings multipl
breakdown share held share held float held institut hold institut holdersholdershar report outvaluevanguard group inc price row associ wellington manag compani massachusett servic fmr morgan america northern trust top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard price row capit appreci spdr etf mf seri trust i-mf valu parnassu equiti vanguard institut fund-institut price row chip growth fund fidel ishar corporation| march
developmentsdanah announc spin dental busi independ publicli trade compani corpor announc intent spin dental segment independ publicly-trad compani dentalco transact intend tax-fre sharehold expect complet second half believ dental busi effect stand-alone compani greater focu around organ inorgan invest opportun danah announc quarterli dividend corpor announc board director approv regular quarterli dividend share payabl onjuli holder record onjun acquir integr dna technolog corpor integr dna announc enter definit agreement acquir privately-held provid high-valu consum genom applic molecular biolog qpcr next gener sequenc synthet biolog gene edit molecular diagnost june corporation| march
perform
compar
roa roi roe ttm
basi stood
respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit corporation| march
consensu view analyst trend stock
rate expect
compar
 growth
rate
dhr forward price-to-earnings
higher
dhr avgfive-year growth forecast usdgrowth high day day day estim comparisondhrindustri avg avgprice/earn yield corporation| march
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim
current qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate corporation| march
stock price movement show upward trend septemb declin later
dip octob
stock gave neg return period averag volum trade
period
stock price volatil past one year surg septemb
stock gave return past one year rang stock
stock price shown upward trend past year
stock given total return last year
crispidea price target maintain base forward price-to-earnings multipl
ep deliv strong result due growth revenu strong oper
margin expans double-digit ep growth four five platform deliv mid-singl digit growth
recommend buy rate stock base perform
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
